CN118359699A - 白细胞介素-22的治疗性衍生物 - Google Patents

白细胞介素-22的治疗性衍生物 Download PDF

Info

Publication number
CN118359699A
CN118359699A CN202410470634.7A CN202410470634A CN118359699A CN 118359699 A CN118359699 A CN 118359699A CN 202410470634 A CN202410470634 A CN 202410470634A CN 118359699 A CN118359699 A CN 118359699A
Authority
CN
China
Prior art keywords
derivative
disease
derivatives
disorder
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410470634.7A
Other languages
English (en)
Chinese (zh)
Inventor
K·萨斯-厄鲁姆
R·约根森
S·B·约根森
H·托格森
T·霍格詹森
M·P·B·桑德里尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saituoqi Pharmaceutical Pte Ltd
Original Assignee
Saituoqi Pharmaceutical Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saituoqi Pharmaceutical Pte Ltd filed Critical Saituoqi Pharmaceutical Pte Ltd
Publication of CN118359699A publication Critical patent/CN118359699A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
CN202410470634.7A 2019-11-07 2020-11-09 白细胞介素-22的治疗性衍生物 Pending CN118359699A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19207766.7 2019-11-07
EP19207766.7A EP3819307A1 (en) 2019-11-07 2019-11-07 Therapeutic derivatives of interleukin-22
PCT/EP2020/081523 WO2021089875A1 (en) 2019-11-07 2020-11-09 Therapeutic derivatives of interleukin-22
CN202080077355.4A CN114761422B (zh) 2019-11-07 2020-11-09 白细胞介素-22的治疗性衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080077355.4A Division CN114761422B (zh) 2019-11-07 2020-11-09 白细胞介素-22的治疗性衍生物

Publications (1)

Publication Number Publication Date
CN118359699A true CN118359699A (zh) 2024-07-19

Family

ID=68502950

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410470634.7A Pending CN118359699A (zh) 2019-11-07 2020-11-09 白细胞介素-22的治疗性衍生物
CN202080077355.4A Active CN114761422B (zh) 2019-11-07 2020-11-09 白细胞介素-22的治疗性衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080077355.4A Active CN114761422B (zh) 2019-11-07 2020-11-09 白细胞介素-22的治疗性衍生物

Country Status (19)

Country Link
US (5) US11806403B2 (cg-RX-API-DMAC10.html)
EP (2) EP3819307A1 (cg-RX-API-DMAC10.html)
JP (2) JP2023502005A (cg-RX-API-DMAC10.html)
KR (1) KR20220097921A (cg-RX-API-DMAC10.html)
CN (2) CN118359699A (cg-RX-API-DMAC10.html)
AU (1) AU2020378648A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022008497A2 (cg-RX-API-DMAC10.html)
CA (1) CA3160338A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022001185A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022005889A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220249A (cg-RX-API-DMAC10.html)
GE (2) GEAP202415970A (cg-RX-API-DMAC10.html)
IL (1) IL292657A (cg-RX-API-DMAC10.html)
MX (1) MX2022005547A (cg-RX-API-DMAC10.html)
MY (1) MY209488A (cg-RX-API-DMAC10.html)
PE (1) PE20221279A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022551107A1 (cg-RX-API-DMAC10.html)
SA (1) SA522432487B1 (cg-RX-API-DMAC10.html)
WO (1) WO2021089875A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2021207662A1 (en) * 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
CN115955976A (zh) * 2020-04-17 2023-04-11 小利兰·斯坦福大学董事会 工程化白介素-22多肽及其用途
EP4389138A1 (en) 2022-12-22 2024-06-26 Cytoki Pharma ApS Dosage regimen for interleukin-22 derivatives
JP2025542282A (ja) 2022-12-22 2025-12-25 サイトカイ・ファーマ・アーペーエス インターロイキン－２２誘導体の投薬レジメン
CN119708194A (zh) * 2023-09-28 2025-03-28 南京诺艾新生物技术有限公司 Il-22突变体及其制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR106F (cg-RX-API-DMAC10.html) 1964-12-21
CA2718634A1 (en) 2008-03-21 2009-09-24 Wyeth Llc Antibodies against interleukin-10-like cytokines and uses therefor
TW201143790A (en) * 2010-05-13 2011-12-16 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
JP2013533227A (ja) * 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
ES2800983T3 (es) * 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
CA2878825A1 (en) 2012-07-10 2014-01-16 The Uab Research Foundation Compositions and methods for modulation of il-20 family cytokine activity
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
WO2015038938A1 (en) * 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US10695406B2 (en) 2014-05-27 2020-06-30 The University Of Queensland Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent
MA41794A (fr) * 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
CN106146668A (zh) 2015-04-01 2016-11-23 中国人民解放军第二军医大学 长效白细胞介素22的制备方法及其用途
HK1257747A1 (zh) * 2015-07-15 2019-10-25 Protagonist Therapeutics Inc. 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
IL321812A (en) * 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
CN111655717A (zh) 2018-01-26 2020-09-11 豪夫迈·罗氏有限公司 IL-22 Fc融合蛋白及使用方法
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
CN115955976A (zh) 2020-04-17 2023-04-11 小利兰·斯坦福大学董事会 工程化白介素-22多肽及其用途
US20240279297A1 (en) 2021-05-11 2024-08-22 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
EP4089107A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22

Also Published As

Publication number Publication date
KR20220097921A (ko) 2022-07-08
US12226487B2 (en) 2025-02-18
PE20221279A1 (es) 2022-09-05
CN114761422B (zh) 2026-01-02
US20260014257A1 (en) 2026-01-15
US20240108731A1 (en) 2024-04-04
CN114761422A (zh) 2022-07-15
JP2023083380A (ja) 2023-06-15
CL2022001185A1 (es) 2023-02-03
MY209488A (en) 2025-07-12
BR112022008497A2 (pt) 2022-07-26
EP4055035A1 (en) 2022-09-14
US20230381320A1 (en) 2023-11-30
MX2022005547A (es) 2022-07-04
US11806403B2 (en) 2023-11-07
JP7479539B2 (ja) 2024-05-08
EP3819307A1 (en) 2021-05-12
US12447211B2 (en) 2025-10-21
PH12022551107A1 (en) 2023-11-20
GEAP202415970A (en) 2024-12-25
US20220347304A1 (en) 2022-11-03
SA522432487B1 (ar) 2024-10-01
CR20220249A (es) 2022-08-19
JP2023502005A (ja) 2023-01-20
WO2021089875A1 (en) 2021-05-14
IL292657A (en) 2022-07-01
GEP20257757B (en) 2025-04-10
AU2020378648A1 (en) 2022-06-23
CO2022005889A2 (es) 2022-07-29
US20240252649A1 (en) 2024-08-01
CA3160338A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
JP7479539B2 (ja) インターロイキン－２２の治療用誘導体
TWI670281B (zh) Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
ES2620111T3 (es) Análogos de glucagón
ES2793773T3 (es) Interferón porcino pegilado y métodos de utilización del mismo
CN105829339B (zh) 胰高血糖素-glp-1-gip三重激动剂化合物
JP2017222651A (ja) 代謝障害及び疾患の治療のための組成物、使用及び方法
ES2898718T3 (es) Método para preparar un complejo polipeptídico fisiológicamente activo
CN117597357A (zh) 白细胞介素-22的治疗性衍生物
US20240279297A1 (en) Therapeutic derivatives of interleukin-22
CN117616035A (zh) 白介素-22的治疗性衍生物
JP7801104B2 (ja) ポリエチレングリコール（ｐｅｇ）－インターロイキン１１（ｉｌ－１１）コンジュゲートを生成するための反応中間体、および、ｐｅｇ－ｉｌ－１１コンジュゲートを精製する方法
TW202140074A (zh) Fgf-21結合物調配物
JP7667582B2 (ja) レナラーゼアゴニスト活性を有する安定なペプチド
US20230310631A1 (en) Therapeutic use of glucagon derivative or conjugate thereof for liver disease
WO2025162423A1 (zh) 针对glp-1r、gipr和gcgr的三激动剂
HK40108760A (en) Therapeutic derivatives of interleukin-22
US20230310630A1 (en) Therapeutic use of combination comprising triple agonistic long-acting conjugate or triple agonist
EA049770B1 (ru) Терапевтические производные интерлейкина-22
JP2025542282A (ja) インターロイキン－２２誘導体の投薬レジメン

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40108760

Country of ref document: HK